Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial.

Tardif JC, Grégoire J, L'Allier PL, Ibrahim R, Lespérance J, Heinonen TM, Kouz S, Berry C, Basser R, Lavoie MA, Guertin MC, Rodés-Cabau J; Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators.

JAMA. 2007 Apr 18;297(15):1675-82. Epub 2007 Mar 26.

PMID:
17387133
2.

Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial.

Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lespérance J, Lüscher TF, Paolini JF, Tawakol A, Waters DD; Can HDL Infusions Significantly QUicken Atherosclerosis REgression (CHI-SQUARE) Investigators.

Eur Heart J. 2014 Dec 7;35(46):3277-86. doi: 10.1093/eurheartj/ehu171. Epub 2014 Apr 29.

3.

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators.

JAMA. 2006 Apr 5;295(13):1556-65. Epub 2006 Mar 13.

PMID:
16533939
4.

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial.

Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R.

JAMA. 2003 Nov 5;290(17):2292-300.

PMID:
14600188
5.

Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.

Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE.

JAMA. 2016 Dec 13;316(22):2373-2384. doi: 10.1001/jama.2016.16951.

PMID:
27846344
6.

Emerging high-density lipoprotein infusion therapies: fulfilling the promise of epidemiology?

Tardif JC.

J Clin Lipidol. 2010 Sep-Oct;4(5):399-404. doi: 10.1016/j.jacl.2010.08.018. Epub 2010 Aug 27.

PMID:
21122683
7.

Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano.

Nicholls SJ, Tuzcu EM, Sipahi I, Schoenhagen P, Crowe T, Kapadia S, Nissen SE.

J Am Coll Cardiol. 2006 Mar 7;47(5):992-7. Epub 2006 Feb 9.

8.

Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial.

Nicholls SJ, Bakris GL, Kastelein JJ, Menon V, Williams B, Armbrecht J, Brunel P, Nicolaides M, Hsu A, Hu B, Fang H, Puri R, Uno K, Kataoka Y, Bash D, Nissen SE.

JAMA. 2013 Sep 18;310(11):1135-44. doi: 10.1001/jama.2013.277169.

PMID:
23999933
9.

Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE.

JAMA. 2007 Feb 7;297(5):499-508.

PMID:
17284700
10.

Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study.

Räber L, Taniwaki M, Zaugg S, Kelbæk H, Roffi M, Holmvang L, Noble S, Pedrazzini G, Moschovitis A, Lüscher TF, Matter CM, Serruys PW, Jüni P, Garcia-Garcia HM, Windecker S; IBIS 4 (Integrated Biomarkers and Imaging Study-4) Trial Investigators (NCT00962416).

Eur Heart J. 2015 Feb 21;36(8):490-500. doi: 10.1093/eurheartj/ehu373. Epub 2014 Sep 2.

PMID:
25182248
11.

Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome.

Rodés-Cabau J, Tardif JC, Cossette M, Bertrand OF, Ibrahim R, Larose E, Grégoire J, L'allier PL, Guertin MC.

Am J Cardiol. 2009 Sep 15;104(6):750-7. doi: 10.1016/j.amjcard.2009.05.009.

PMID:
19733706
12.

Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial.

Hirohata A, Yamamoto K, Miyoshi T, Hatanaka K, Hirohata S, Yamawaki H, Komatsubara I, Murakami M, Hirose E, Sato S, Ohkawa K, Ishizawa M, Yamaji H, Kawamura H, Kusachi S, Murakami T, Hina K, Ohe T.

J Am Coll Cardiol. 2010 Mar 9;55(10):976-82. doi: 10.1016/j.jacc.2009.09.062.

13.

Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials.

Sipahi I, Tuzcu EM, Wolski KE, Nicholls SJ, Schoenhagen P, Hu B, Balog C, Shishehbor M, Magyar WA, Crowe TD, Kapadia S, Nissen SE.

Ann Intern Med. 2007 Jul 3;147(1):10-8.

PMID:
17606956
14.

Comparison of intravascular ultrasound and quantitative coronary angiography for the assessment of coronary artery disease progression.

Berry C, L'Allier PL, Grégoire J, Lespérance J, Levesque S, Ibrahim R, Tardif JC.

Circulation. 2007 Apr 10;115(14):1851-7. Epub 2007 Mar 26.

15.

Effect of the BET Protein Inhibitor, RVX-208, on Progression of Coronary Atherosclerosis: Results of the Phase 2b, Randomized, Double-Blind, Multicenter, ASSURE Trial.

Nicholls SJ, Puri R, Wolski K, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Hu B, Uno K, Kataoka Y, Herrman JP, Merkely B, Borgman M, Nissen SE.

Am J Cardiovasc Drugs. 2016 Feb;16(1):55-65. doi: 10.1007/s40256-015-0146-z.

PMID:
26385396
16.

ApoA-I induction as a potential cardioprotective strategy: rationale for the SUSTAIN and ASSURE studies.

Nicholls SJ, Gordon A, Johannson J, Ballantyne CM, Barter PJ, Brewer HB, Kastelein JJ, Wong NC, Borgman MR, Nissen SE.

Cardiovasc Drugs Ther. 2012 Apr;26(2):181-7. doi: 10.1007/s10557-012-6373-5.

PMID:
22349989
17.

Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial.

Nissen SE, Nicholls SJ, Wolski K, Rodés-Cabau J, Cannon CP, Deanfield JE, Després JP, Kastelein JJ, Steinhubl SR, Kapadia S, Yasin M, Ruzyllo W, Gaudin C, Job B, Hu B, Bhatt DL, Lincoff AM, Tuzcu EM; STRADIVARIUS Investigators.

JAMA. 2008 Apr 2;299(13):1547-60. doi: 10.1001/jama.299.13.1547. Epub 2008 Apr 1.

PMID:
18387931
18.

Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ; CAMELOT Investigators.

JAMA. 2004 Nov 10;292(18):2217-25.

PMID:
15536108
19.

Coronary endothelium-dependent vasoreactivity and atheroma volume in subjects with stable, minimal angiographic disease versus non-ST-segment-elevation myocardial infarction: an intravascular ultrasound study.

Puri R, Nicholls SJ, Nissen SE, Brennan DM, Andrews J, Liew GY, Nelson AJ, Carbone A, Copus B, Tuzcu EM, Beltrame JF, Worthley SG, Worthley MI.

Circ Cardiovasc Imaging. 2013 Sep;6(5):674-82. doi: 10.1161/CIRCIMAGING.113.000460. Epub 2013 Jun 27.

20.

Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.

Mani P, Uno K, St John J, Tuzcu EM, Nissen SE, Nicholls SJ.

Am J Cardiol. 2014 Sep 1;114(5):681-5. doi: 10.1016/j.amjcard.2014.06.001. Epub 2014 Jun 18.

PMID:
25030535

Supplemental Content

Support Center